True early cancer detection involves finding microscopic tumor DNA in blood samples. This can identify cancer years before it's visible on an MRI, creating an opportunity for a patient's own immune system to potentially eliminate it before it ever becomes a clinical disease.

Data from trials like Niagara suggests a powerful new paradigm for assessing treatment success. Combining urine tumor DNA (uTDNA) for local disease and circulating tumor DNA (ctDNA) for systemic relapse offers a more dynamic view than traditional pathology and is poised to become the superior surrogate endpoint in bladder cancer trials.

A key conceptual shift is viewing ctDNA not as a statistical risk marker, but as direct detection of molecular residual disease (MRD). This framing, similar to how a CT scan identifies metastases, explains its high positive predictive value and justifies its use in making critical treatment decisions.

While the need for prospective trials dominates the ctDNA discussion, a more fundamental obstacle is the lack of standardization between assay types (e.g., tumor-informed vs. agnostic). Without a common measurement approach, data from disparate trials cannot be pooled to create a universally accepted surrogate endpoint for regulatory approval.

Circulating tumor DNA (ctDNA) testing is described as unequivocally the most prognostic tool available for colorectal cancer. Patients who remain serially negative have a minimal recurrence risk, while a positive result almost universally predicts a future clinical recurrence by 6-8 months.

AI identified circulating tumor DNA (ctDNA) testing as a highly sensitive method for detecting cancer recurrence earlier than scans or symptoms. Despite skepticism from oncologists who deemed it unproven, the speaker plans to use it for proactive monitoring—a strategy he would not have known about otherwise.

The InVigor11 study was the first to show that detecting recurrence via a ctDNA test before it's visible on scans is not just a prognostic sign, but an actionable clinical state. Intervening with therapy at this early stage was proven to improve patient outcomes, establishing a new paradigm for cancer surveillance.

Tumor-informed assays like Signatera sequence a patient's tumor to create a personalized test, making it highly sensitive but taking 3-4 weeks. Tumor-uninformed assays are faster (1 week) but less sensitive as they screen for a generic panel of cancer mutations.

ctDNA testing does more than identify targetable mutations. The mutant allele fraction provides a quasi-volumetric measure of tumor burden, and its early clearance on therapy (as seen in MONALEESA-3) is a strong prognostic indicator for survival, adding value beyond standard radiographic assessment.